SLC5A2 and hydrops fetalis: SGLT2 inhibitors, such as dapagliflozin, are considered a substantial addition to HF treatment, irrespective of LVEF, diabetic status, or the acuity of the clinical setting, and appear to be effective and well tolerated in most clinical HF scenarios [27].